FDA Issues Draft Guidance on Validating Alternatives to Animal Testing

The FDA has released draft guidance aimed at helping drug developers validate New Approach Methodologies (NAMs) as alternatives to traditional animal testing. This move signals a formal shift away from animal testing as the default regulatory standard, favouring human-centric data to accelerate the delivery of safe, effective therapies to market.

The Center for Drug Evaluation and Research is now prioritising NAMs – technologies such as organ-on-chips, 3D organoids and AI-driven in silico modelling – as more reliable predictors of human response. The guidance outlines how companies can demonstrate the scientific validity of these tools to gain regulatory confidence.

The Commissioner emphasizes the necessity of this transition, stating: "Technological advances are allowing us to move beyond animal testing in drug development, which has a poor track record of predicting safety and efficacy in humans."

The FDA has incorporated four definitive pillars by which pharma companies can qualify and safely integrate NAMs into their applications to ensure these modern tools meet regulatory standards: context of use (clearly defining how and where the tool will be used in the regulatory process), human biological relevance (demonstrating how the model accurately assesses human toxicity), technical characterisation (establishing the method is reliable, robust and consistent), and fit-for-purpose (ensuring the data directly aids in regulatory decision-making and drug approval).

The guidance notes that a fit-for-purpose NAM could replace an animal study or fill a data gap not addressed by animal-based methods, or provide additional information when traditional non-clinical models are unavailable. For example, an in vitro NAM might justify why certain animal species may not yield useful information, according to the document, which is open for comment until 18th May.

As the FDA released its draft guidance, the NIH said it will invest $150 million in human-based research to develop the tools needed to reduce the use of animal models, the first awards under the recently announced Complement Animal Research in Experimentation (Complement-ARIE) programme.

In a statement, the US regulator said the NAMs guidance is a "major milestone" on that path and "reflects the FDA's commitment to moving away from using animal testing as the default method for gaining drug safety information."

While the guidance provides a general roadmap, it does not mandate specific technologies or address specific methodologies or drug discovery applications. Instead, the FDA encourages developers to meet with its specialised medical teams early in the preclinical stage of testing and to consult with its experts on the specifics of "indication-, disease-, organ-, and endpoint […] applications."

The document is the latest stage in the FDA's roadmap for reducing animal testing over the next three to five years, published in April last year, and follows other measures such as the recent publication of guidance aimed at reducing or stopping toxicity studies of monoclonal antibody-based drugs in non-human primates (NHPs).

The Secretary of Health and Human Services emphasised the broader impact of the guidance on future innovation, noting: "Clear validation expectations will help modern tools earn regulatory confidence and speed safer, more effective therapies to patients."